Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer
-
Add time:07/18/2019 Source:sciencedirect.com
This study was aimed at developing a nanoparticle strategy to overcome acquired resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on biodegradable PLGA nanoparticles, erlotinib-cyclodextrin (Erlo-CD) complex was prepared using β-cyclodextrin sulfobutyl ether, which was in turn loaded in the core of PLGA nanoparticles using multiple emulsion solvent evaporation. Nanoparticles were characterized for size distribution, entrapment and loading efficiency, in-vitro release, and therapeutic efficacy against different lung cancer cells. Effect of formulation on cell cycle, apoptosis, and other markers was evaluated using flow cytometry and western blotting studies. The efficacy of optimized nanoformulation was evaluated using a clinically relevant in-vitro 3D-spheroid model. Results showed that Erlo-CD loaded nanoparticles (210 ± 8 nm in size) demonstrated 3-fold higher entrapment (61.5 ± 3.2% vs 21.9 ± 3.7% of plain erlotinib loaded nanoparticles) with ~5% loading efficiency and sustained release characteristics. Developed nanoparticles demonstrated significantly improved therapeutic efficacy against NSCLC cells in terms of low IC50 values and suppressed colony forming ability of cancer cells, increased apoptosis, and autophagy inhibition. Interestingly, 3D spheroid study demonstrated better anticancer activity of Erlo-CD nanoparticles compared to plain erlotinib. Present study has shown a premise to improve therapeutic efficacy against erlotinib-resistant lung cancer using modified nanoErlo formulations.
We also recommend Trading Suppliers and Manufacturers of Erlotinib hydrochloride (cas 183319-69-9). Pls Click Website Link as below: cas 183319-69-9 suppliers
Prev:Simultaneous determination of temperature and erlotinib by novel carbon-based sensitive nanoparticles
Next:Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing Erlotinib hydrochloride (cas 183319-69-9)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing Erlotinib hydrochloride (cas 183319-69-9)07/19/2019
- Simultaneous determination of temperature and erlotinib by novel carbon-based sensitive nanoparticles07/17/2019
- The redox mechanism investigation of non-small cell lung cancer drug: Erlotinib via theoretical and experimental techniques and its host–guest detection by β-Cyclodextrin nanoparticles modified glassy carbon electrode07/16/2019
- [11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice07/15/2019
- Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay07/14/2019
- Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application07/13/2019
- Recrystallization of Erlotinib hydrochloride (cas 183319-69-9) and fulvestrant using supercritical antisolvent process07/12/2019
- Use of roller compaction and fines recycling process in the preparation of Erlotinib hydrochloride (cas 183319-69-9) tablets07/11/2019
-
Health and Chemical more >